Tracks how rectal cancer responds to treatment before surgery
Studies how adults with rectal cancer respond to treatment before surgery.
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- Commack, Harrison, Middletown, Montvale, New York, and Rockville Centre, United StatesSee the 6 sites
- Trial code
- Registry title
- A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 9 Oct 2024
- Expected to end
- 9 Oct 2027
- Type of study
- Interventional
- Treatments tested
- Endoscopy
- Record updated
- 2 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with rectal cancer (adenocarcinoma) who are about to start standard treatment before surgery: chemoradiation followed by chemotherapy.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Invasive adenocarcinoma of the rectum, confirmed by tissue examination, with no known mismatch repair deficiency or Her2 amplification.
- Earlier treatment
- People must plan to start standard treatment: fluoropyrimidine-based chemoradiation (capecitabine preferred, or 5-FU), then CAPEOX, FOLFOX or FOLIRINOX. Prior radiation to the pelvis is not allowed.
- Biomarker or test result
- No known mismatch repair deficiency and no Her2 amplification.
Main reasons for not taking part
- Another current or past cancer that could affect the safety or results of the study treatment
- Earlier external beam radiation to the pelvis, or prostate seed implants (brachytherapy)
- Pregnant or breastfeeding
- Not using effective contraception
- Cannot have MR imaging, or takes blood thinners that rule out tumor biopsies
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- 18 years of age or older on day of signing informed consent
- Have a histologically confirmed diagnosis of invasive adenocarcinoma of the rectum with no known mismatch repair deficiency or Her2 amplification
- Eligible for and plan to initiate standard-of-care therapy with any of the following regimens:; Induction fluoropyrimidine (capecitabine [preferred] or 5-FU) based chemoradiation; With plan for consolidative CAPEOX, FOLFOX, or FOLIRINOX
- Woman with childbearing potential who are negative for pregnancy test (urine or blood) and who agree to use an effective contraceptive method. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. Reliable contraception should be used from the time of screening and must be continued throughout the duration of treatment as per standard of care
Who cannot take part
- Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
- Patients with prior external beam radiation therapy to the pelvis or brachytherapy seed implantation of the prostate
- Patients who are pregnant or breastfeeding
- Men or women not using effective contraception
- Patients with a contraindication to MR imaging
- Patients on blood thinners prohibiting endoluminal tumor biopsies
This trial is currently available in United States.
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack, United StatesContact: Paul Romesser, MDTaking people
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison, United StatesContact: Paul Romesser, MDTaking people
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, United StatesContact: Paul Romesser, MDTaking people
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, United StatesContact: Paul Romesser, MDTaking people
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesContact: Paul Romesser, MDTaking people
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)Rockville Centre, United StatesContact: Paul Romesser, MDTaking people
About the trial
What the trial wants to find out
The purpose of the study is to learn more about how the body responds to standard treatment (chemoradiation and chemotherapy). The study will use the results of testing down on participants' blook, tissue, and scans to learn more about how people with rectal cancer respond to chemoradiation and chemotherapy treatment and if it is useful for predicting whether a person's cancer get better, gets worse, or stats the same after treatment.
The group in the trial
- Participants with Rectal CancerTreatment being tested
Participants will be diagnosed with rectal cancer and will be undergoing standard-of-care neoadjuvant therapy.
Treatment: Endoscopy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- DISCRN in Rectal Cancer: DISseCting Response to Neoadjuvant Therapy in Rectal Cancer
- Plain-language title
- Tracks how rectal cancer responds to treatment before surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 June 2026